MedTrace Logo

Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control

NCT00918879 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2011-09-26

Study results available
· View outcomes & findings →

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and exercise.

Conditions

Interventions

DRUG

Saxagliptin

Oral tablet, once daily for 24 weeks

DRUG

Placebo

Oral tablet, once daily for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Peter Ohman, MD, PhD · AstraZeneca, Wilmington, USA

  • Deborah Price, MSc · AstraZeneca, Wilmington, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00918879 on ClinicalTrials.gov